Philips Says Test Results Show Recalled Sleep Devices Unlikely To Cause Harm

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Koninklijke Philips NV PHG released an update on a comprehensive test and research program related to the recalled respiratory devices.
The company says the risk assessments are completed for 95% of the first-generation DreamStation, System One, and DreamStation Go devices.
The medical device maker said the latest tests indicated that potential patient exposure to foam particulate matter (PM) and volatile organic compounds (VOCs) from the PE-PUR foam within these devices is "unlikely to result in an appreciable harm to health in patients."
The test and research program has been conducted with five independent, certified testing laboratories. The results have been reviewed and assessed by third-party qualified experts, Philips Respironics, and an external medical panel.
Related: Philips Recalls Some Masks Used With Respiratory Devices Over Potential Injury Risk
Last month, the company faced further trouble as it recalled certain reworked DreamStations respiratory devices due to assigned incorrect or duplicate serial numbers during initial programming.
In March, the company said it intends to negotiate settlements related to its global recall of respiratory equipment this year.
Also read: Philips Q1 Results
Price Action: PHG shares are trading higher by 0.34% at $20.84 premarket on the last check Tuesday.
Photo Via Company

Momentum34.35

Growth31.09

Quality17.02

Value16.87

Short

Medium

Long